Dr. Patrick Soon Shiong
About Dr. Patrick Soon Shiong
Dr. Patrick Soon-Shiong - Executive Chairman at ImmunityBio
Dr. Patrick Soon-Shiong currently serves as the Executive Chairman and Global Chief Scientific and Medical Officer at ImmunityBio. His role involves overseeing scientific and medical operations, guiding the company's research and development efforts, and contributing to significant advancements in immunotherapy and oncology. ImmunityBio focuses on developing novel therapies to combat various cancers and incurable diseases using the body’s immune system.
Dr. Patrick Soon-Shiong at the American Urological Association Annual Conference
At the Annual Conference of the American Urological Association, Dr. Patrick Soon-Shiong participated in a fireside chat hosted by Professor Sam S. Chang from the Vanderbilt Cancer Program. During this discussion, Dr. Soon-Shiong delved into the mechanisms of ANKTIVA® and its potential impact on treating BCG unresponsive non-muscle invasive bladder cancer (NMIBC). The chat highlighted the IL-15 superagonist's ability to achieve durable complete responses in affected patients.
Insights on Cancer Immunotherapy by Dr. Patrick Soon-Shiong
Dr. Patrick Soon-Shiong provided insights into cancer immunotherapy, explaining how the transformation of MHC- to MHC+ can rescue exhausted or immune-evaded T cells. He detailed how this mechanism forms the basis of the Cancer Moonshot initiative, which was announced in 2016. Dr. Soon-Shiong emphasized that this approach applies to a wide range of tumor types that have entered the escape phase, representing a significant advancement in cancer treatment.
Overview of QUILT Program by Dr. Patrick Soon-Shiong
In his presentation about the QUILT (QUantum Immuno-Oncology Lifelong Trial) program, Dr. Patrick Soon-Shiong discussed how the transformation of MHC- to MHC+ applies to various tumor types. This program seeks to utilize combinations of immunotherapies to create a more effective treatment plan for patients, aiming to keep tumors in a managed state throughout one's lifetime. The initiative embodies a holistic and patient-centric approach to cancer care.
ANKTIVA®: Activation of NK and T Cells
Dr. Patrick Soon-Shiong explained how ANKTIVA® activates natural killer (NK) cells and T cells, which leads to complete durable responses in cancer treatment. This activation is critical in prompting the body's immune system to more effectively target and eliminate cancer cells. The discussed mechanism underscores the potential impact of ANKTIVA® in providing lasting therapeutic outcomes for patients with various forms of cancer.